
Global Endoparasiticide Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Endoparasiticide market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Endoparasiticide include Novartis AG, Merck, Eli Lilly, Bayer AG, Zoetis, Virbac, Vetoquinol, Elanco and Ceva Sante Animlae, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Endoparasiticide, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Endoparasiticide, also provides the sales of main regions and countries. Of the upcoming market potential for Endoparasiticide, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Endoparasiticide sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Endoparasiticide market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Endoparasiticide sales, projected growth trends, production technology, application and end-user industry.
Endoparasiticide Segment by Company
Novartis AG
Merck
Eli Lilly
Bayer AG
Zoetis
Virbac
Vetoquinol
Elanco
Ceva Sante Animlae
Boehringer Ingelheim
Endoparasiticide Segment by Type
Ear Tags
Feed Additives
Tablets
Injectables
Endoparasiticide Segment by Application
Veterinary Hospitals or Clinics
Home Care Settings
Animal Farms
Endoparasiticide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endoparasiticide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endoparasiticide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endoparasiticide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Endoparasiticide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Endoparasiticide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Endoparasiticide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Endoparasiticide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
According to APO Research, The global Endoparasiticide market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Endoparasiticide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Endoparasiticide include Novartis AG, Merck, Eli Lilly, Bayer AG, Zoetis, Virbac, Vetoquinol, Elanco and Ceva Sante Animlae, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Endoparasiticide, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Endoparasiticide, also provides the sales of main regions and countries. Of the upcoming market potential for Endoparasiticide, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Endoparasiticide sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Endoparasiticide market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Endoparasiticide sales, projected growth trends, production technology, application and end-user industry.
Endoparasiticide Segment by Company
Novartis AG
Merck
Eli Lilly
Bayer AG
Zoetis
Virbac
Vetoquinol
Elanco
Ceva Sante Animlae
Boehringer Ingelheim
Endoparasiticide Segment by Type
Ear Tags
Feed Additives
Tablets
Injectables
Endoparasiticide Segment by Application
Veterinary Hospitals or Clinics
Home Care Settings
Animal Farms
Endoparasiticide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endoparasiticide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endoparasiticide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endoparasiticide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Endoparasiticide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Endoparasiticide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Endoparasiticide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Endoparasiticide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Table of Contents
197 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Endoparasiticide Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Endoparasiticide Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Endoparasiticide Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Endoparasiticide Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Endoparasiticide Market Dynamics
- 2.1 Endoparasiticide Industry Trends
- 2.2 Endoparasiticide Industry Drivers
- 2.3 Endoparasiticide Industry Opportunities and Challenges
- 2.4 Endoparasiticide Industry Restraints
- 3 Endoparasiticide Market by Manufacturers
- 3.1 Global Endoparasiticide Revenue by Manufacturers (2020-2025)
- 3.2 Global Endoparasiticide Sales by Manufacturers (2020-2025)
- 3.3 Global Endoparasiticide Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Endoparasiticide Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Endoparasiticide Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Endoparasiticide Manufacturers, Product Type & Application
- 3.7 Global Endoparasiticide Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Endoparasiticide Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Endoparasiticide Players Market Share by Revenue in 2024
- 3.8.3 2024 Endoparasiticide Tier 1, Tier 2, and Tier 3
- 4 Endoparasiticide Market by Type
- 4.1 Endoparasiticide Type Introduction
- 4.1.1 Ear Tags
- 4.1.2 Feed Additives
- 4.1.3 Tablets
- 4.1.4 Injectables
- 4.2 Global Endoparasiticide Sales by Type
- 4.2.1 Global Endoparasiticide Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Endoparasiticide Sales by Type (2020-2031)
- 4.2.3 Global Endoparasiticide Sales Market Share by Type (2020-2031)
- 4.3 Global Endoparasiticide Revenue by Type
- 4.3.1 Global Endoparasiticide Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Endoparasiticide Revenue by Type (2020-2031)
- 4.3.3 Global Endoparasiticide Revenue Market Share by Type (2020-2031)
- 5 Endoparasiticide Market by Application
- 5.1 Endoparasiticide Application Introduction
- 5.1.1 Veterinary Hospitals or Clinics
- 5.1.2 Home Care Settings
- 5.1.3 Animal Farms
- 5.2 Global Endoparasiticide Sales by Application
- 5.2.1 Global Endoparasiticide Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Endoparasiticide Sales by Application (2020-2031)
- 5.2.3 Global Endoparasiticide Sales Market Share by Application (2020-2031)
- 5.3 Global Endoparasiticide Revenue by Application
- 5.3.1 Global Endoparasiticide Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Endoparasiticide Revenue by Application (2020-2031)
- 5.3.3 Global Endoparasiticide Revenue Market Share by Application (2020-2031)
- 6 Global Endoparasiticide Sales by Region
- 6.1 Global Endoparasiticide Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Endoparasiticide Sales by Region (2020-2031)
- 6.2.1 Global Endoparasiticide Sales by Region (2020-2025)
- 6.2.2 Global Endoparasiticide Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Endoparasiticide Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Endoparasiticide Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Endoparasiticide Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Endoparasiticide Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Endoparasiticide Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Endoparasiticide Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Endoparasiticide Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Endoparasiticide Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Endoparasiticide Revenue by Region
- 7.1 Global Endoparasiticide Revenue by Region
- 7.1.1 Global Endoparasiticide Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Endoparasiticide Revenue by Region (2020-2025)
- 7.1.3 Global Endoparasiticide Revenue by Region (2026-2031)
- 7.1.4 Global Endoparasiticide Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Endoparasiticide Revenue (2020-2031)
- 7.2.2 North America Endoparasiticide Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Endoparasiticide Revenue (2020-2031)
- 7.3.2 Europe Endoparasiticide Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Endoparasiticide Revenue (2020-2031)
- 7.4.2 Asia-Pacific Endoparasiticide Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Endoparasiticide Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Endoparasiticide Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Novartis AG
- 8.1.1 Novartis AG Comapny Information
- 8.1.2 Novartis AG Business Overview
- 8.1.3 Novartis AG Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Novartis AG Endoparasiticide Product Portfolio
- 8.1.5 Novartis AG Recent Developments
- 8.2 Merck
- 8.2.1 Merck Comapny Information
- 8.2.2 Merck Business Overview
- 8.2.3 Merck Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Merck Endoparasiticide Product Portfolio
- 8.2.5 Merck Recent Developments
- 8.3 Eli Lilly
- 8.3.1 Eli Lilly Comapny Information
- 8.3.2 Eli Lilly Business Overview
- 8.3.3 Eli Lilly Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Eli Lilly Endoparasiticide Product Portfolio
- 8.3.5 Eli Lilly Recent Developments
- 8.4 Bayer AG
- 8.4.1 Bayer AG Comapny Information
- 8.4.2 Bayer AG Business Overview
- 8.4.3 Bayer AG Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Bayer AG Endoparasiticide Product Portfolio
- 8.4.5 Bayer AG Recent Developments
- 8.5 Zoetis
- 8.5.1 Zoetis Comapny Information
- 8.5.2 Zoetis Business Overview
- 8.5.3 Zoetis Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Zoetis Endoparasiticide Product Portfolio
- 8.5.5 Zoetis Recent Developments
- 8.6 Virbac
- 8.6.1 Virbac Comapny Information
- 8.6.2 Virbac Business Overview
- 8.6.3 Virbac Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Virbac Endoparasiticide Product Portfolio
- 8.6.5 Virbac Recent Developments
- 8.7 Vetoquinol
- 8.7.1 Vetoquinol Comapny Information
- 8.7.2 Vetoquinol Business Overview
- 8.7.3 Vetoquinol Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Vetoquinol Endoparasiticide Product Portfolio
- 8.7.5 Vetoquinol Recent Developments
- 8.8 Elanco
- 8.8.1 Elanco Comapny Information
- 8.8.2 Elanco Business Overview
- 8.8.3 Elanco Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Elanco Endoparasiticide Product Portfolio
- 8.8.5 Elanco Recent Developments
- 8.9 Ceva Sante Animlae
- 8.9.1 Ceva Sante Animlae Comapny Information
- 8.9.2 Ceva Sante Animlae Business Overview
- 8.9.3 Ceva Sante Animlae Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Ceva Sante Animlae Endoparasiticide Product Portfolio
- 8.9.5 Ceva Sante Animlae Recent Developments
- 8.10 Boehringer Ingelheim
- 8.10.1 Boehringer Ingelheim Comapny Information
- 8.10.2 Boehringer Ingelheim Business Overview
- 8.10.3 Boehringer Ingelheim Endoparasiticide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Boehringer Ingelheim Endoparasiticide Product Portfolio
- 8.10.5 Boehringer Ingelheim Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Endoparasiticide Value Chain Analysis
- 9.1.1 Endoparasiticide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Endoparasiticide Production Mode & Process
- 9.2 Endoparasiticide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Endoparasiticide Distributors
- 9.2.3 Endoparasiticide Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.